Literature DB >> 34611794

Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology.

William A Hall1,2,3, Mandana Kamgar4,5,6, Beth A Erickson7,4,5, Sara Beltrán Ponce7, Susan Tsai4,5, Marja T Nevalainen8, Kathleen K Christians4,5, Ben George5,6, Kulwinder S Dua5,9, Abdul H Khan5,9, Douglas B Evans4,5, Asfar S Azmi10.   

Abstract

Panc reatic ductal adenocarcinoma (PDAC) is a devastating malignancy. There have been few advances that have substantially improved overall survival in the past several years. On its current trajectory, the deaths from PDAC are expected to cross that from all gastrointestinal cancers combined by 2030. Radiation therapy is a technically very complex modality that bridges multiple different treatment strategies. It represents a hybrid among advanced diagnostic imaging, local (often ablative) intervention, and heterogeneous biological mechanisms contributing to normal and oncologic cell kill. In this article, we bring an overview of the several promising strategies that are currently being investigated to improve outcomes using radiation therapy for patients with PDAC.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Advances in radiation for pancreatic cancer; Novel RT techniques; Pancreatic radiation therapy; Radiation sensitization

Mesh:

Year:  2021        PMID: 34611794      PMCID: PMC8767496          DOI: 10.1007/s10555-021-09993-z

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.237


  55 in total

1.  Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.

Authors:  Ross A Abrams; Kathryn A Winter; William F Regine; Howard Safran; John P Hoffman; Robert Lustig; Andre A Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-01       Impact factor: 7.038

2.  Pancreas SBRT: Who, What, When, Where, and How….

Authors:  Vincent Bernard; Joseph M Herman
Journal:  Pract Radiat Oncol       Date:  2019-11-21

Review 3.  Combining radiation and immunotherapy: a new systemic therapy for solid tumors?

Authors:  Chad Tang; Xiaohong Wang; Hendrick Soh; Steven Seyedin; Maria Angelica Cortez; Sunil Krishnan; Erminia Massarelli; David Hong; Aung Naing; Adi Diab; Daniel Gomez; Huiping Ye; John Heymach; Ristuko Komaki; James P Allison; Padmanee Sharma; James W Welsh
Journal:  Cancer Immunol Res       Date:  2014-09       Impact factor: 11.151

Review 4.  Proton therapy for pancreatic cancer.

Authors:  Romaine C Nichols; Soon Huh; Zuofeng Li; Michael Rutenberg
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

5.  A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group.

Authors: 
Journal:  Ann Surg       Date:  1979-02       Impact factor: 12.969

Review 6.  The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities.

Authors:  Won Jin Ho; Elizabeth M Jaffee; Lei Zheng
Journal:  Nat Rev Clin Oncol       Date:  2020-05-12       Impact factor: 66.675

7.  Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.

Authors:  Frank T Zenke; Astrid Zimmermann; Christian Sirrenberg; Heike Dahmen; Vladimir Kirkin; Ulrich Pehl; Thomas Grombacher; Claudia Wilm; Thomas Fuchss; Christiane Amendt; Lyubomir T Vassilev; Andree Blaukat
Journal:  Mol Cancer Ther       Date:  2020-03-27       Impact factor: 6.261

8.  MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways.

Authors:  Adriana Estrada-Bernal; Moumita Chatterjee; S Jaharul Haque; Linlin Yang; Meredith A Morgan; Shweta Kotian; David Morrell; Arnab Chakravarti; Terence M Williams
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.

Authors:  Edmund Poon; Stefanie Mullins; Amanda Watkins; Geoffrey S Williams; Jens-Oliver Koopmann; Gianfranco Di Genova; Marie Cumberbatch; Margaret Veldman-Jones; Shaun E Grosskurth; Vasu Sah; Alwin Schuller; Corrine Reimer; Simon J Dovedi; Paul D Smith; Ross Stewart; Robert W Wilkinson
Journal:  J Immunother Cancer       Date:  2017-08-15       Impact factor: 13.751

10.  Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.

Authors:  Somnath Mukherjee; Christopher N Hurt; John Bridgewater; Stephen Falk; Sebastian Cummins; Harpreet Wasan; Tom Crosby; Catherine Jephcott; Rajarshi Roy; Ganesh Radhakrishna; Alec McDonald; Ruby Ray; George Joseph; John Staffurth; Ross A Abrams; Gareth Griffiths; Tim Maughan
Journal:  Lancet Oncol       Date:  2013-03-06       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.